New York Life Investment Management’s Esperion Therapeutics ESPR Stock Holding History

New York Life Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47M	Buy	+466,632	New	+$1.31M	0.01%	617

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

New York Life Investment Management's ESPR Position: Q2 2026 in Review

New York Life Investment Management opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 466,632 shares worth $1.47M. The stake represents 0.01% of the portfolio and ranks #617 among its holdings.

191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

New York Life Investment Management held 466,632 shares of Esperion Therapeutics worth $1.47M as of Q2 2026.
Esperion Therapeutics was a new New York Life Investment Management position in Q2 2026.
Esperion Therapeutics made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #617 holding.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.